Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images

Cancer/Radiotherapie

Volumn 17, Issue 3, 2013, Pages 215-220

  Udrescu, C ^a   De Bari, B ^a,c   Rouviere O ^b   Ruffion, A ^a   Michel Amadry, G ^a   Jalade, P ^a   Devonec, M ^a   Colombel, M ^b   Chapet, O ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Gold markers; Hormone therapy; IGRT; Prostate repositioning

Indexed keywords

ANTIANDROGEN; GOLD;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; DOSIMETRY; ELECTRIC POTENTIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGE RECONSTRUCTION; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE VOLUME; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; COMPUTER ASSISTED RADIOTHERAPY; FIDUCIAL MARKER; PROSTATE TUMOR; RADIOGRAPHY;

ANDROGEN ANTAGONISTS; FIDUCIAL MARKERS; GOLD; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84882943133     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2013.01.015     Document Type: Article

References (27)

1. Chiavassa S., Brunet G., Gaudaire S., Munos-Llagostera C., Delpon G., Lisbona A. Radiothérapie conformationnelle avec modulation d'intensité: analyse des résultats des contrÔles précliniques, expérience du centre René-Gauducheau. Cancer Radiother 2011, 15:265-269.
2. Cazoulat G., Lesaunier M., Simon A., Haigron P., Acosta O., Louvel G., et al. De la radiothérapie guidée par l'image à la radiothérapie guidée par la dose. Cancer Radiother 2011, 15:691-698.
3. Delpon G., Llagostera C., Le Blanc M., Rio E., Supiot S., Mahé M.A., et al. Quelle radiothérapie guidée par l'image pour quels patients ? Expérience concomitante de l'utilisation de trois dispositifs d'imagerie de repositionnement dans le cas du cancer de la prostate. Cancer Radiother 2009, 13:399-407.
4. Dudouet P., Boutry C., Mounié G., Latorzeff I., Thouveny F., Redon A. Système d'imagerie par tomographie conique de basse énergie (kV) de Varian : expérience de Montauban. Cancer Radiother 2009, 13:375-383.
5. Jouyaux F., de Crevoisier R., Manens J.-P., Bellec J., Cazoulat G., Haigron P., et al. Haute dose dans la prostate par radiothérapie guidée par l'image : apport de l'arcthérapie avec modulation d'intensité du faisceau. Cancer Radiother 2010, 14:679-689.
6. Pommier P., Morelle M., Perrier L., de Crevoisier R., Laplanche A., Dudouet P., et al. Évaluation économique prospective de la radiothérapie guidée par l'image des cancers de la prostate dans le cadre du programme national de soutien aux thérapeutiques innovantes et coÛteuses. Cancer Radiother 2012, 16:444-451.
7. van Haaren P.M.A., Bel A., Hofman P., van Vulpen M., Kotte A.N.T.J., van der Heide U.A. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol 2009, 90:291-298.
8. Kron T., Thomas J., Fox C., Thompson A., Owen R., Herschtal A., et al. Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol 2010, 95:191-197.
9. Kudchadker R., Lee A.K., Yu Z.H., Johnson J.L., Zhang L., Zhang Y., et al. Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys 2009, 74:1283-1289.
10. Kupelian P.A., Willoughby T.R., Meeks S.L., Forbes A., Wagner T., Maach M., et al. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys 2005, 62:1291-1296.
11. Logadóttir A., Korreman S., Petersen P.M. Comparison of the accuracy and precision of prostate localization with 2D-2D and 3D images. Radiother Oncol 2011, 98:175-180.
12. Moman M.R., van der Heide U.A., Kotte A.N.T.J., van Moorselaar R.J.A., Bol G.H., Franken S.P.G., et al. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 2010, 96:38-42.
13. Shirato H., Harada T., Harabayashi T., Hida K., Endo H., Kitamura K., et al. Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:240-247.
14. Gauthier I., Carrier J.F., Béliveau-Nadeau D., Fortin B., Taussky D. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys 2009, 74:1128-1133.
15. Lerma F.A., Liu S.Z., Liu B., Li H., Yi B., Amin P., et al. Image guided intermediate-stage prostate cancer IMRT: minimum margins and an ideal alignment strategy [Abstract]. Int J Radiat Oncol Biol Phys 2008, 72:S565.
16. Madsen B.L., Hsi R.A., Pham H.T., Presser J., Esagui L., Corman J., et al. Intrafractional stability of the prostate using a stereotactic radiotherapy technique. Int J Radiat Oncol Biol Phys 2003, 57:1285-1291.
17. Edelman S., Liauw S.L., Rossi P.J., Cooper S., Jani A.B. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys 2012, 83:1473-1479.
18. Quon H., Cheung P.C.F., Loblaw D.A., Morton G., Pang G., Szumacher E., et al. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Int J Radiat Oncol Biol Phys 2012, 82:898-905.
19. He T.T., Tanyi J., Laub W., Hung A. Effect of concurrent hormone therapy on the positional stability of electromagnetic transponders implanted in the prostate [Abstract]. Int J Radiat Oncol Biol Phys 2010, 78:S700.
20. King B.L., Butler W.M., Merrick G.S., Kurko B.S., Reed J.L., Murray B.C., et al. Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 2011, 79:1350-1357.
21. Pouliot J., Aubin M., Langen K.M., Liu Y.M., Pickett B., Shinohara K., et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003, 56:862-866.
22. Sanguineti G., Marcenaro M., Franzone P., Foppiano F., Vitale V. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 2003, 66:151-157.
23. Delouya G., Carrier J.F., Béliveau-Nadeau D., Donath D., Taussky D. Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiother Oncol 2010, 96:43-47.
24. Nichol A.M., Brock K.K., Lockwood G.A., Moseley D.J., Rosewall T., Warde P.R., et al. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. Int J Radiat Oncol Biol Phys 2007, 67:48-56.
25. Poggi M.M., Gant D.A., Sewchand W., Warlick W.B. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys 2003, 56:1248-1251.
26. Dehnad H., Nederveen A.J., van der Heide U.A., van Moorselaar R.J.A., Hofman P., Lagendijk J.J.W. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol 2003, 67:295-302.
27. Helou J., Nasr E., Nasr D.N., Fares A., Elie N., Maroun M., et al. Réduction du volume prostatique par hormonothérapie avant radiothérapie conformationnelle pour cancer de la prostate [Abstract]. Cancer Radiother 2009, 13:684.